FDA grants fast-track status to Innocoll's surgical implant

11/19/2008 | Pharmaceutical Business Review Online

The FDA has given fast-track designation to Innocoll's Gentamicin, a biodegradable surgical implant. The device is being tested in two late-stage studies as a supplement to systemic antibiotic treatment aimed at preventing surgical-site infections among high-risk patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ